FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043099150> ?p ?o ?g. }

• W3043099150 endingPage "3190" @default.
• W3043099150 startingPage "3180" @default.
• W3043099150 abstract "Abstract There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center for International Blood and Marrow Transplant Research who received first RIC allo-transplant between 2001 and 2015 were studied. Patients were excluded if they received cord blood or identical twin transplant, total body irradiation in conditioning, or graft-versus-host disease (GVHD) prophylaxis with in vitro T-cell depletion. Primary outcome was overall survival (OS), secondary end points were leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and GVHD. Multivariate survival model was used with adjustment for patient, leukemia, and transplant-related factors. A total of 622 patients received FM and 791 received FB RIC. Compared with FB, the FM group had fewer transplant in complete remission (CR), fewer matched sibling donors, and less usage of anti-thymocyte globulin or alemtuzumab. More patients in the FM group received marrow grafts and had transplantation before 2005. OS was significantly lower within the first 3 months posttransplant in the FM group (hazard ratio [HR] = 1.82, P &lt; .001), but was marginally superior beyond 3 months (HR = 0.87, P = .05). LFS was better with FM compared with FB (HR = 0.89, P = .05). NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P &lt; .001). Long-term relapse was lower with FM (HR = 0.65, P &lt; .001). Analysis restricted to patients with CR showed comparable results. In conclusion, compared with FB, the FM RIC showed a marginally superior long-term OS and LFS and a lower relapse rate. A lower OS early posttransplant within 3 months was largely the result of a higher early NRM." @default.
• W3043099150 created "2020-07-23" @default.
• W3043099150 creator A5000083234 @default.
• W3043099150 creator A5001697191 @default.
• W3043099150 creator A5002993817 @default.
• W3043099150 creator A5003455280 @default.
• W3043099150 creator A5003966906 @default.
• W3043099150 creator A5007601060 @default.
• W3043099150 creator A5011030256 @default.
• W3043099150 creator A5011386306 @default.
• W3043099150 creator A5011761696 @default.
• W3043099150 creator A5011868189 @default.
• W3043099150 creator A5012489403 @default.
• W3043099150 creator A5015521146 @default.
• W3043099150 creator A5017044459 @default.
• W3043099150 creator A5017327825 @default.
• W3043099150 creator A5017442411 @default.
• W3043099150 creator A5017803794 @default.
• W3043099150 creator A5018065917 @default.
• W3043099150 creator A5019979915 @default.
• W3043099150 creator A5020415674 @default.
• W3043099150 creator A5022714308 @default.
• W3043099150 creator A5023628069 @default.
• W3043099150 creator A5023700544 @default.
• W3043099150 creator A5023728016 @default.
• W3043099150 creator A5026497723 @default.
• W3043099150 creator A5026533672 @default.
• W3043099150 creator A5029278364 @default.
• W3043099150 creator A5030283354 @default.
• W3043099150 creator A5031370568 @default.
• W3043099150 creator A5033734703 @default.
• W3043099150 creator A5034264716 @default.
• W3043099150 creator A5035051206 @default.
• W3043099150 creator A5036654919 @default.
• W3043099150 creator A5037454036 @default.
• W3043099150 creator A5038249770 @default.
• W3043099150 creator A5040815890 @default.
• W3043099150 creator A5041335047 @default.
• W3043099150 creator A5041526386 @default.
• W3043099150 creator A5042176968 @default.
• W3043099150 creator A5042915360 @default.
• W3043099150 creator A5043016347 @default.
• W3043099150 creator A5043033429 @default.
• W3043099150 creator A5045603763 @default.
• W3043099150 creator A5047787264 @default.
• W3043099150 creator A5048300954 @default.
• W3043099150 creator A5048969336 @default.
• W3043099150 creator A5050068696 @default.
• W3043099150 creator A5051793137 @default.
• W3043099150 creator A5051833337 @default.
• W3043099150 creator A5052100524 @default.
• W3043099150 creator A5052281366 @default.
• W3043099150 creator A5052357377 @default.
• W3043099150 creator A5058557833 @default.
• W3043099150 creator A5058862489 @default.
• W3043099150 creator A5058925624 @default.
• W3043099150 creator A5061865992 @default.
• W3043099150 creator A5062116571 @default.
• W3043099150 creator A5062691289 @default.
• W3043099150 creator A5062834108 @default.
• W3043099150 creator A5064856519 @default.
• W3043099150 creator A5065085606 @default.
• W3043099150 creator A5065815399 @default.
• W3043099150 creator A5066894053 @default.
• W3043099150 creator A5068817380 @default.
• W3043099150 creator A5068834306 @default.
• W3043099150 creator A5069441736 @default.
• W3043099150 creator A5069460930 @default.
• W3043099150 creator A5069685528 @default.
• W3043099150 creator A5069729940 @default.
• W3043099150 creator A5070043884 @default.
• W3043099150 creator A5070132319 @default.
• W3043099150 creator A5072463255 @default.
• W3043099150 creator A5074706721 @default.
• W3043099150 creator A5076550283 @default.
• W3043099150 creator A5078402672 @default.
• W3043099150 creator A5079417201 @default.
• W3043099150 creator A5083504452 @default.
• W3043099150 creator A5083687455 @default.
• W3043099150 creator A5084915025 @default.
• W3043099150 creator A5085360755 @default.
• W3043099150 creator A5085486670 @default.
• W3043099150 creator A5086494836 @default.
• W3043099150 creator A5087218742 @default.
• W3043099150 creator A5088341793 @default.
• W3043099150 creator A5088962035 @default.
• W3043099150 creator A5090082095 @default.
• W3043099150 date "2020-07-14" @default.
• W3043099150 modified "2023-10-14" @default.
• W3043099150 title "Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report" @default.
• W3043099150 cites W1479909146 @default.
• W3043099150 cites W1480670630 @default.
• W3043099150 cites W1970975433 @default.
• W3043099150 cites W1987350756 @default.
• W3043099150 cites W1992090010 @default.
• W3043099150 cites W1995851214 @default.
• W3043099150 cites W1996320020 @default.
• W3043099150 cites W2029173845 @default.

• next